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1. Introduction 
1.1 Acute cardiac collapse 
Patients with cardiogenic shock and cardiac arrest still have a very poor prognosis despite 
recent improvements in treatment algorithms. Acute coronary ischemia and myocardial 
infarction (AMI) is the most frequent cause of cardiogenic shock and cardiac arrest. 
Improved survival has been shown for patients with AMI treated with urgent coronary 
revascularization. Also, improved pre-hospital logistics and cooling after successful 
resuscitation has shown possible benefit for cardiac arrest patients. However, a large 
proportion of patients with AMI and acute cardiac collapse do not survive until hospital 
discharge. These represent a group where current treatment options are often unsuccessful.  
This far, advances in pharmacological treatment have produced various substances with 
theoretical and hemodynamic promise but clinical effects have been scarce. The use of 
vasopressors and inotropes generally has failed to show effect on mortality in cardiogenic 
shock and cardiac arrest. Recently a large clinical trial showed no effect of intravenous 
medication on survival for cardiac arrest victims (Figure 1).  
Lately, more thought provoking data have emerged indicating a possible negative effect of 
vasopressor therapy on cardiac and cerebral perfusion during circulatory collapse and 
resuscitation. Clinical reports have further suggested a possible relationship between the use 
of adrenaline like drugs and increased mortality in patients with acute myocardial infarction 
and shock. 
Mechanical support with intra-aortic balloon pump (IABP) counter pulsation therapy has 
been routinely used for several years in cardiogenic shock but the clinical usefulness is 
currently being strongly questioned. In cardiac arrest, optimally performed chest 
compressions are critical for successful re-establishment of intrinsic pulse giving rhythm 
(Figure 2). Mechanical compression-decompression devices have also shown impressive 
hemodynamic effects experimentally but a benefit compared with conventional chest 
compressions has not been found in clinical trials.  
Both IABP and the compression-decompression devices have been associated with bleeding 
complications. 
The mechanisms behind refractory cardiogenic shock and cardiac arrest may be many and 
are yet not clearly defined. It seems clear however, that with the pharmacological and 
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Fig. 1. Survival after witnessed out-of-hospital cardiac arrest with and without any 
intravenous (IV) drug therapy. Olavsveengen et al. JAMA. 2009 Nov 25;302(20):2222-9 
 
 
Detrimental effect of interrupted chest compressions 
Fig. 2. Interrupted chest compressions (3-10-15 seconds) dramatically reduce the chance of 
successful defibrillation. Yu et al. Circulation 2002 Jul 16;106(3):368-72 
mechanical approaches for hemodynamic support currently in use, vital organ perfusion 
and cardiac recovery is not reliably obtained sufficiently to have life saving effect.  
A major focus for future research in the field of acute cardiac collapse should be on 
development of approaches for improved circulatory support.  
1.2 Cardiac assist therapy in stable patients vs. acute hemodynamic collapse 
Left ventricular assist devices (LVADs) can reduce myocardial workload and improve vital 
organ perfusion in patients with impaired cardiac function. In severe chronic heart failure 
LVAD therapy has been shown to substantially improve long term survival. Continuous 
flow devices have shown clinical benefit and are regularly used for long term treatment of 
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terminal heart failure. The theoretical added benefit of additional right ventricular assist 
device (RVAD) therapy has not been shown to improve results.  
Most LVAD systems require surgical implantation and are thus less well suited for acute use 
in critically ill patients. Patients with acute circulatory collapse require urgent circulatory 
support in order to prevent irreversible tissue ischemia and vital organ damage. In some 
cases, the time window for effective treatment may be too short to permit for required 
logistical and technical procedures related to surgical intervention. Furthermore, the 
potential to cause further compromise in hemodynamic and metabolic status with complex 
surgical procedures can be deleterious in these already marginal patients.  
Surgical LVADs as well as different types of cardiopulmonary support (CPS) systems, 
commonly used in routine cardiac surgery have been employed in patients with acute 
cardiac collapse including cardiogenic shock and cardiac arrest. Results have been 
encouraging with respect to improving hemodynamics in treated patients. However, clinical 
results for the most critically ill have not been shown to improve with the devices and 
technologies tested this far. The lack of a predictable generalised benefit with surgical 
cardiac assist therapy in acute hemodynamic collapse may be related to complicated 
implantation procedures and high risk of complications.  
1.3 Percutaneous left ventricular assist devices (PVADs) 
Recently, cardiac support systems with percutaneous access have been developed. 
Percutaneous devices could offer rapid placement and reduced risk of complications 
compared with surgical devices. These obvious advantages compared with surgical assist 
systems in the critically ill could outweigh limitations in blood delivery related to the 
smaller size of percutaneous devices. 
Two different types of PVAD devices have been approved for clinical use (Impella LP2.5, 
TandemHeart) (Figure 3). The Impella LP 2.5 is a transfemoraly deployed 12 F impeller 
pump deployed in the left ventricle on a pigtail shaped catheter. Maximal delivery is 
2.5L/min, the pump outlet is situated in the ascending aorta in the level of the coronary 
artery ostia. The TandemHeart requires 21F venous and 15F arterial groin access as well as 
trans-septal puncture in order to obtain a left-atrial to femoral-artery blood delivery of 
maximally 5L/min. Deployment times have been found to be longer with the latter device 
but the risk of procedure related complications remain low with both systems. 
Both devices have been studied in clinical use and have shown potential to improve 
hemodynamics in cardiogenic shock and acute myocardial infarction. The use of PVAD 
therapy has also been advocated and tested as backup hemodynamic support in scheduled 
high risk cardiac intervention including percutaneous coronary intervention (PCI) and 
trans-catheter aortic valve implantation (TAVI).  
In acute hemodynamic collapse and in resuscitated patients requiring immediate circulatory 
support, the less complicated and more rapidly deployed LP 2.5 may be the technically most 
attractive of the available devices. The LP 2.5 also offers a more physiological blood delivery 
and unloading as blood is pumped directly out of the left ventricle into the pre-coronary 
and pre-cerebral arterial circulation. It is yet unclear however, if the limited delivery of 2.5 
liters with the Impella device is sufficient to sustain adequate systemic circulation and 
cardiac unloading over time in a critical clinical setting. Potentially, improved support can 
be achieved with the larger (21) Impella LP 5.0 pump for which percutaneous deployment 
may also be feasible. 
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Fig. 3. PVADs in clinical use.  
A: 1)Impella LP 2.5, 2) in-situ schematic drawing.  
B: TandemHeart-pump, catheters, in-situ schematic drawing 
2. Problems to be solved 
2.1 Irreversible ischemic injury 
Vital organ hypo-perfusion causing ischemic dysfunction and injury is a major challenge. In 
acute hemodynamic collapse tissue damage due to inadequate blood delivery can be severe. 
The thresholds for irreversible ischemic injury causing cell death and organ dysfunction are 
different in different tissues. Vital organs with high metabolic rates as the heart and brain 
may be particularly prone to injury during short term hypo-perfusion and ischemia. In 
particular, the risk of acute brain injury is high when cardio-pulmonary resuscitation needs 
to be performed. Lowering metabolic rates and oxygen consumption with cooling has 
shown potential to reduce ischemic injury in the heart as well as in the brain after cardiac 
arrest. Cardiac volume unloading with PVAD therapy can also reduce cardiomyocyte 
oxygen consumption and may have potential to reduce ischemic injury. Contrarily, 
vasopressor substances may contribute to increased myocardial injury by increasing 
metabolic rates in an ischemic heart muscle. 
Mechanisms behind cell dysfunction and death during ischemia being investigated and a 
wide variety of pathways and mediators have been described. Furthermore, Emerging 
1 2 
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Catheters
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therapeutic targets for pharmacological intervention to prevent ischemic injury have been 
identified, particularly in the field of reperfusion injury. 
Activation of the mithochondrial trans-membrane pore MPTP leads to mithochondrial 
swelling and subsequent cell death and is by many considered the final common path way 
for ischemic cell necrosis (Figure 4). A wide range of novel therapies aiming at modulating 
MPTP and the pathways leading to its activation and inactivation are currently being 
investigated but a definite clinical breakthrough has not yet been reached. 
 
 
Fig. 4. Mitochondrial permeability transition pore plays a key role in cardiomyocyte necrosis 
after ischemic stress. Lacerda et al. Cardiovasc Res. 2009;84:201-208 
2.2 Persistent cardiac arrest 
The most common cause of cardiac arrest is myocardial ischemia. 
Cardiac arrest has a high mortality and morbidity despite recent developments in 
resuscitation methods, educational programs and improved logistics. Clinical results are 
often poor even after successful re-establishment of intrinsic circulation. Long term 
neurological sequelae are present in up-to 60% of patients with current advanced therapy 
including cooling, revascularization and other adjunctive therapy. In patients with 
persistent cardiac arrest defined as pulseless cardiac rhythm unresponsive to advanced 
cardiac life support (ACLS) prognosis is even worse. 
The setting of persistent cardiac arrest represents the extreme of acute critical cardiac failure 
where mechanical intervention is absolutely required in order to sustain circulation. 
Persistent cardiac arrest is present in a substantial portion of cardiac arrest victims; with up 
to 60%-80% reported in some studies. 
Mechanisms behind refractory cardiac arrest remain to be definitely established. There is 
evidence that sustained coronary ischemia may be an important factor behind shock 
resistant ventricular fibrillation in ischemic cardiac arrest. Regional ischemic metabolic 
changes with interstitial hyperkalemia and acidosis contribute to cardiomyocyte electrical 
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instability causing ineffective depolarization patterns which impair re-establishment of 
spontaneous circulation with defibrillation. 
Reports of successful treatment of persistent VF with left ventricular unloading catheters 
have also been presented indicating that increased left ventricular pressure during cardiac 
arrest can make the heart refractory to cardioversion. The combined treatment of acute 
cardiac collapse patients with percutaneous revascularization and a PVAD may in theory be 
able to improve the return of spontaneous circulation and could also improve cardiac 
recovery and tissue perfusion after initial stabilisation. 
2.3 Life support during revascularization 
During ischemic cardiac arrest, chest compressions and coronary revascularisation should 
be performed optimally in order to maximalise the clinical potential of both treatments.  
Interruptions of chest compressions and impaired coronary visualisation can reduce the 
prognostic benefit of acute revascularisation in persistent ischemic cardiac arrest. Chest 
compressions can cause traumatic injury to the chest and heart which could hamper the 
effect of otherwise successful treatment. Possibly, the use of percutaneous devices may be 
more suited for acute treatment in these critically compromised patients. 
In the cardiac catheterization laboratory, a percutaneous left ventricular assist device can be 
deployed within few minutes and may be useful both by improving hemodynamics and by 
obviating the need for chest compressions during percutaneous coronary intervention 
during persistent ischemic cardiac arrest. 
Of the currently available percutaneous assist devices the Impella 2.5 is likely to be more 
suited for hyper-acute use during cardiac arrest due to less complicated and faster 
deployment procedures. This device has been studied in experimental models of persistent 
ischemic cardiac arrest and results have been promising. 
2.4 Previous research 
Current resuscitation algorithms are complex and include defibrillation, manual chest 
compressions and the use of vasopressor drugs. The hemodynamic and clinical effects of 
conventional resuscitation with external chest compressions and medical therapy are in 
many cases suboptimal. Results from large clinical trials indicate a substantial potential for 
improvement of current advanced cardiac life support.  
When spontaneous circulation can not be rapidly restored after witnessed resuscitated 
cardiac arrest (persistent cardiac arrest) reported mortality is close to 100% with 
conventional treatment.  
Sophisticated pharmacological approaches to improve cardiac efficacy and blood pressure 
have not been able to improve outcomes in this population despite impressive pre-clinical 
data. Additionally, recent studies indicate vasopressor drugs may have detrimental effects 
on cardiac and cerebral function. In cardiogenic shock, vasopressor use has been associated 
with impaired outcomes in the setting of acute myocardial infarction. It may be reasonable 
to suggest that inotropes and vasopressor substances do not represent the pharmacological 
agents most likely to make a significant impact on patient survival in this field in the future. 
Mechanical assist devices represent an attractive approach in the treatment of cardiac 
collapse. Intra aortic balloon pump therapy in cardiogenic shock and compression-
decompression devices in cardiac arrest are in widespread routine clinical use despite 
debatable clinical data. Similary as for inotropes and vasopressor therapy, it may be inferred 
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that the encouraging blood pressure augmenting effects of the devices overshadow the lack 
of survival benefit and the risk of such treatment in clinical practice. 
Other treatment modalities such as volume expansion and abdominal compression for 
increasing venous return have shown hemodynamic benefits comparable to that of 
vasopressors but clinical use and testing has been limited. 
From a hemodynamic standpoint, LVADs as well as CPS represent attractive approaches for 
improving outcomes in acute cardiac collapse requiring resuscitation. This far, various 
surgically deployed assist systems and external mechanical compression-decompression 
devices have been investigated in cardiac arrest. Hemodynamic effects have been promising 
but clinical results have remained poor.  
In the clinical setting, acute myocardial ischemia is a major cause of cardiac arrest. Some 
studies indicate that urgent PCI may improve outcomes in patients with ST-elevation on the 
electrocardiogram after return of spontaneous circulation. The subgroup of patients with 
ROSC and subsequent ST-elevation on ECG constitute only a small part of cardiac arrest 
patients. Acute coronary revascularisation has not been proven to be beneficial for the large 
portion of patients without ST elevation or without ROSC. 
However, cardiac arrest is commonly caused by acute coronary ischemia in the absence of 
obvious non-cardiac causes (Figure 5). Furthermore, the presence of coronary ischemia may 
reduce the success rate of defibrillation causing persistent ventricular fibrillation. On this 
basis, patients with suspected acute coronary ischemia and persistent cardiac arrest are 
increasingly being treated with acute revascularization with cardiac catheterization even 
with ongoing resuscitation.  
 
Fig. 5. High incidence of coronary artery disease in cardiac arrest victims. Spaulding et al.N 
Engl J Med 336:1629-1633 June 5, 1997 
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3. Our data 
3.1 Impella LP 2.5 in cardiac arrest 
We performed the first experimental assessment of PVAD therapy during ischemic 
ventricular fibrillation in 2005. In a randomized porcine model we showed that blood 
delivery to the systemic circulation could be achieved with a PVAD during cardiac arrest 
without simultaneous chest compressions and without vasopressor. It was also found that 
intravenous fluid loading improved pump delivery during cardiac arrest in a randomized 
comparison with conservative fluid infusion.  The complete results have been published 
previously (Tuseth et al, Crit. Care Med., 2008).  
Design and results are outlined below. 
16 porcine subjects under general anesthesia were randomized to percutaneous left 
ventricular assist device support either with conventional or with intensified fluid infusion 
as only hemodynamic interventions during cardiac arrest. All procedures were performed 
with percutaneous access. 
After randomization for fluid infusion, cardiac arrest was induced by balloon occlusion of 
the proximal left anterior descending artery. The percutaneous left ventricular assist device 
and fluid infusions were started after ventricular fibrillation had been induced. Brain, 
kidney, myocardial tissue perfusion and cardiac index were measured with the 
microspheres injection technique at baseline, 3 and 15 minutes. Additional hemodynamic 
monitoring continued until 30 minutes.   
At 30 minutes LVAD function was sustained in 11/16 animals (8/8 intensified fluid vs. 3/8 
conventional fluid) and was associated with intensified fluid loading (P<0.001). Mean 
cardiac index at 3 minutes of VF was 1.2 L.min/m2 (29% of baseline, P<0.05). Mean 
perfusion at 3 minutes was 65% in the brain and 74% in the myocardium compared to 
Baseline (P=NS) with no further significant change after 15 minutes. 
3.2 Prevention of cerebral ischemia with Impella LP 2.5 during cardiac arrest 
In a second study, using a similar protocol, our group investigated the effect of PVAD-
assisted circulation during cardiac arrest on cerebral ischemic injury. Using cerebral 
microdialysis we found that ischemic cerebral metabolism and injury assessed with 
microdialysis could be avoided during a prolonged period of cardiac arrest. The same study 
also showed that PVAD function and hemodynamics were maintained for an extended 
period of 45 minutes of cardiac arrest.   
The complete results have been published previously. 
Design and results are outlined below. (Tuseth et al, Resuscitation , 2009). 
12 anesthetized pigs in narcosis had cerebral microdialysis and pressure catheters implanted 
via craniotomy; otherwise the principal experimental set-up was comparable to paper 1.   
Cerebral microdialysis markers (glucose, pyruvate, lactate, glycerol) were analyzed after 20 
and 40 minutes of VF with assisted circulation.  Tissue perfusion was measured with 
microspheres injections.   
After 20 minutes of VF, cerebral microdialysis showed no ischemic changes (P=NS to 
Baseline for glucose, glycerol, lactate, pyruvate and lactate/pyruvate ratio) in subjects with 
maintained end-tidal CO2 values above 1.3 kPa (predicted survivors). After 40 minutes only 
lactate showed a significant change compared to Baseline (P<0.05) (Figure 6). Microspheres 
confirmed blood flow to the brain at 57% and myocardium at 72% of baseline after 15 
minutes (P<0.05), declining to 22% and 40% after 45 minutes respectively (P=NS). In the 
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predicted non-survivors (end tidal CO2 below 1.3 kPa after 20 minutes, n=6) microdialysis 
indicated cerebral ischemia at 20 minutes and tissue perfusion by microspheres was below 
1% of Baseline (all P<0.05). End-tidal CO2 identified subjects with and without successful 
circulation.  
 
 
Fig. 6. Lactate/Pyruvate ratio from cerebral microdialysis is a sensitive marker for ischemic 
cerebral metabolism. Values with PVAD support during ischemic cardiac arrest in dark 
grey, without in light grey, normal values shaded. Values with PVAD support are normal 
during the first 20 minutes and moderately pathological between 20 and 40 minutes 
whereas values without support are immediately critical after onset of ventricular 
fibrillation. Tuseth et al, Resuscitation.2009 Oct;80(10):1197-203. 
3.3 Randomised comparison of PVAD, LVAD and open chest cardiac massage during 
ischemic ventricular fibrillation 
Finally, in a third study, the hemodynamic effects of the PVAD (Impella LP 2.5 (LP2.5)) 
were compared with optimal manual resuscitation using open chest cardiac massage and 
with a larger, surgically deployed LVAD (Impella LP 5.0 (LP5.0)) during VF. 
This experiment compared clinical outcomes assessed by the rates of successful return of 
spontaneous circulation (ROSC) with defibrillation after 20 minutes of ischemic cardiac 
arrest with the three different methods of circulatory support. This study indicated the 
PVAD outperformed optimal conventional resuscitation with open chest cardiac massage 
with regards to myocardial perfusion and obtained similar outcomes for ROSC and cerebral 
perfusion compared to optimal current therapy (OCCM). Compared with a surgical LVAD 
in this clinical setting the PVAD also showed superior results, likely due to a problem with 
aortic regurgitation and shunting with the surgical device in the absence of any intrinsic 
circulation. 
The complete results have been published previously (Tuseth et al, Resuscitation, 2010). 
Design and results are outlined below. 
Baseline 0-20 20-40
min min
25
50
75
100
300
500
Lactate/Pyruvate ratio 
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18 pigs were randomized into 3 groups (all n=6). Surgical preparation including thoracotomy 
was performed in general anesthesia. A Doppler flow probe was placed around the 
pulmonary artery for direct and continuous cardiac output measurement. A catheter was 
inserted into the mid-distal LAD for pressure monitoring and the distal LAD was occluded by 
ligature inducing myocardial ischemia. Microspheres injections were used for measuring of 
tissue-perfusion. VF was induced with diathermy stimulation of the left ventricle.  
After 3 minutes of VF, cardiac output with cardiac massage was 1129 mL.min-1 vs. 1169 
mL.min-1 with the percutaneous- and 570 mL.min-1 with the surgical device (P<0.05 for 
surgical vs. others). End-tidal CO2 was 3.3 kPa with cardiac massage vs. 3.2 kPa with the 
percutaneous- and 2.3 kPa with the surgical device (P<0.05 surgical vs. others). 
Subepicardial perfusion was 0.33 mL.min-1.g-1 with cardiac massage vs. 0.62 mL.min-1.g-1 
with both devices (P<0.05 devices vs. massage), cerebral perfusion was not significantly 
different between groups (all reported values after 3 min cardiac arrest, all P<0.05 vs. 
Baseline, all P= NS for 3 min vs. 15 min). Defibrillation after 20 minutes achieved return of 
spontaneous circulation in 5/6 subjects with cardiac massage vs. 6/6 with the percutaneous- 
and 4/6 with the surgical device (P=NS) (Figure 7).  
 
 
Fig. 7. Rates of successful defibrillation after 20 minutes of persistent ischemic cardiac 
arrest with open chest cardiac massage (OCCM) or PVAD (Impella LP 2.5) or LVAD 
(Impella LP 5.0). Tuseth et al. Resuscitation. 2010 Nov;81(11):1566-70. 
4. Technical considerations 
4.1 Resuscitation 
In the routine clinical setting, manual or mechanical chest compressions are the current 
standard for life support during cardiac arrest. Despite advances in technical performance 
and monitoring, the hemodynamic effects and clinical outcomes still have potential for 
improvement. External devices have been employed with promising hemodynamic results, 
but uncertain clinical benefit. Internal cardiac massage with an open chest has proven 
superior results compared to external methods both in experimental and clinical studies. 
However, the method has not been established in the clinical routine as the technique 
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requires surgical access to the heart and may have risk of complications.  In experimental 
cardiac arrest, OCCM may be considered a clinically relevant reference for optimal CPR. A 
direct comparison of the PVAD to optimal CPR has not been performed previously. 
4.2 Hemodynamic considerations 
In the absence of myocardial contraction during cardiac arrest, blood flow through the 
pulmonary circulation depends on thoracic volume compression and decompression in 
conventional CPR.  In addition, sequential variation of thoracic volume and pressure during 
mechanical ventilation may facilitate blood flow towards the left side circulation.  
Furthermore, blood flow through the pulmonary vasculature is improved by increasing 
central venous pressure and TPR.  With PVAD support without concomitant chest 
compressions during VF, LV filling may be limited. However, with optimal filling conditions, 
the use of the percutaneous impeller device could be feasible during cardiac arrest. 
Intravenous fluid administration can increase venous return, central venous pressures and left 
ventricle filling pressures. Consequently, fluid loading may have potential to improve blood 
delivery to the left ventricle from the right side of the heart in cardiac arrest.  
4.3 End-Tidal CO2 
End-tidal CO2 values can be continuously monitored from the ventilator and may indicate 
the clinical efficacy of CPR during prolonged cardiac arrest. During resuscitation, end-tidal 
CO2 is associated with cerebral perfusion and cardiac output. Cut off values have been 
identified which can be used to predict survival in cardiac arrest.  
4.4 Cerebral injury  
Despite novel therapeutic approaches including hypothermia, emergency revascularization, 
medical intervention and mechanical devices assist devices, ischemic cerebral damage 
remains a major limitation for outcomes after cardiac arrest. Assessment of cerebral blood 
flow can be achieved by various techniques. In experimental studies, perfusion measured by 
microspheres is a reliable approach for assessment of cerebral cortical perfusion and may 
provide relevant hemodynamic information, but can not detect or quantify ischemic injury.  
A recently developed method employs a miniaturized dialysis technique for direct 
evaluation of biochemical markers related to metabolism and injury in different tissues. In 
order to assess cerebral injury, cerebral microdialysis can be performed via a miniature 
dialysis catheter implanted into the cerebral cortex through a small cranial burr hole (Figure 
8). This technique can detect and monitor metabolic changes in the brain at an early stage 
after injury and has been validated in relation to cerebral perfusion and clinical outcomes. 
Limited data exist from previous experimental studies in circulatory arrest. Normal 
reference values have been defined. During cardiac arrest, cerebral microdialysis may give 
highly relevant information for the assessment of the clinical significance of hemodynamic 
interventions.  
4.5 Animal models 
Investigation of previously not tested treatment in cardiac arrest has potential to cause harm 
in a clinical setting. In general, new methodology may have unforeseen complications and 
may also infer with current optimal standard of care. In cardiac arrest, immediate and 
aggressive treatment is required for optimal survival which limits assessment of new 
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Fig. 8. Principles of cerebral microdialysis catheter. Tuseth et al. Interventional 
Cardiology.2009 Dec;1(2):197-208 
hypotheses in human subjects in this setting. Prognosis is critically poor in this subset of 
patients and further research aiming on improving the understanding, and possibly the 
outcomes of cardiac arrest is considered highly relevant. Thus, the use of animal models of 
human disease may be considered appropriate in order to evaluate novel interventions in 
cardiac arrest. Research animals have been used in various protocols to study 
hemodynamics and interventions in cardiac arrest with considerable experimental evidence 
and validated end-points. In this project, PVAD was used to investigate the use of a 
miniature blood pump as hemodynamic support during cardiac arrest without concomitant 
conventional CPR. The device studied is designed for intra-arterial deployment from the 
femoral artery into the left ventricle and requires anatomy similar to that in humans for 
optimal assessment. The selected porcine model offers anatomic and hemodynamic 
conditions close to that in human subjects.  
4.6 Animals  
All three experimental protocols included Norwegian Land Race swine of either sex and 
with weight approximately 50 kg.  Subjects were fasted overnight with free access to water. 
The animals were acclimatized for at least 7 days under controlled temperature, lighting and 
humidity and were fed with a standard diet. The experimental protocols were registered 
and approved by the Norwegian Animal Research Authority and by the local responsible 
laboratory animal veterinarian, and was conducted in accordance with national and 
international laws controlling experiments in live animals. A dose of 330mg acetylsalicylic 
acid was administered orally the day before the procedure in order to reduce the risk of 
coronary thrombus formation during intravascular procedures.  
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4.7 Anesthesia 
After intramuscular premedication with ketamine (20 mg/kg) and atropine (1mg) in the 
neck, ear veins were cannulated. Animals were placed on a warm-water blanket with 
continuous monitoring of rectal temperature and electrocardiogram. Ventilation 
(spontaneous on mask) with O2 and 3% (vaporizer setting) isoflurane (Rhodia, Bristol, 
England) for 2 to 3 min allowed oral intubation. Ventilation was commenced and continued 
with a mixture of N2O (56-57%) and oxygen. The mechanical ventilator (Cato M32000, 
Drägerwerk, Lübeck, Germany) was set to a tidal volume of 10 mL/kg and a frequency of 13 
– 15 cycles/min; with small adjustments aiming at an end-tidal CO2 of 5 %. Anesthesia was 
induced by intravenous loading doses of fentanyl 0.02 mg/kg, midazolam 0.3 mg/kg and 
sodium pentobarbital 15 mg/kg and maintained with continuous infusions of fentanyl 0.02 
mg/kg per h, midazolam 0.3 mg/kg per h, (pancuronium 0.14 mg/kg per h, paper 1) and 
pentobarbital 4 mg/kg per h. Thus, the total fluid substitution for anesthesia amounted to 15 
mL/kg per h.  
4.8 Percutaneous model  
After infiltrating the skin with 0.5% xylocaine the femoral arteries and veins were exposed 
bilaterally and secured by ligatures. Arterial (13F, 6F, 5F) and venous (8F) sheaths were 
inserted. A bolus of 5000 international units of heparin was administered intra-arterially 
after placing the sheaths and repeated every 60 minutes for the duration of the study. A 5F-
pigtail catheter was placed in the left ventricle for injection of microspheres. A 6F 
multipurpose hockey stick catheter served as a guide for the left coronary artery. Right side 
pressures were measured with a Swan Ganz catheter in the pulmonary artery. The Impella 
LP 2.5 (Abiomed, USA) was implanted with the inlet below and the outlet above the aortic 
valve. Aortic pressure and pump output in L/min was recorded from the device module. 
End tidal CO2 was monitored from the mechanical ventilator system. Samples for arterial 
acid-base measurements were taken from the arterial sheaths. Additionally, in paper 1, 
venous blood samples were taken at the same time points as arterial blood.  
The Impella Recover LP 2.5 is a true percutaneous LVAD with a diameter of 4 mm (12F). 
Insertion is by a 13F arterial sheath and deployment into the LV is performed over a 0.14” 
guide wire under fluoroscopic guidance, usually via the femoral artery.  The outlet is in the 
proximal ascending aorta. Positioning is guided by a pressure sensor. 
4.9 Surgical model  
Surgical tracheotomy and suprapubic vesical catheterization were performed directly after 
induction of narcosis. Next, median sternotomy was performed with an oscillating saw. 
After free-dissection of the aorta, a Doppler-flow probe (Medi-Stim Butterfly Flowmeter 
Probe, 21mm, MediStim, Oslo, Norway) was placed around the common pulmonary trunk 
permitting direct measurement of cardiac output. For microspheres administration and 
pressure monitoring, a soft catheter (Feeding tube CH 6 (2mm, 40cm), UNO Plast A/S, 
Hundested, Denmark) was deployed in the left atrium using Seldinger-technique and 
secured by sutures. For pressure monitoring in the LAD, a miniature catheter 
(ABBOCATH®-T 20 G, Venisystems, Sligo, Ireland) was inserted into the mid-distal portion 
of the left anterior descending artery (LAD) with Seldinger-technique and fixated with 
sutures, this also inducing myocardial ischemia distal to the implantation site. Additional 
fluid supplements were administered to compensate for any fluid- and blood-loss during 
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the study aiming to maintain a minimum flow in the pulmonary artery of 3 L.min-1 and also 
optimal filling of the heart visually determined from the surgical field. Trans-esophageal-
echocardiography (TEE) with intravenous bubbles contrast was performed to detect 
potential cardiac defects with shunting of blood at Baseline . Baseline registrations were 
made during spontaneous circulation after 5 minutes of stabilization post-surgery. VF was 
induced by stimulation of the LV by surgical diathermy. Open chest cardiac massage was 
performed using both hands, with the left hand holding the right ventricle and the fingers of 
the right hand holding the left ventricle, performing anterior-posterior compression at a rate 
of approximately 80 min−1. Defibrillation with 50 Joules delivered directly to the 
myocardium was performed after 20 minutes of VF still with mid LAD occlusion. 
The Impella Recover LP 5.0 has a diameter of 7mm (21 F) and a maximal output of 5 liters 
per minute. This device is principally similar to the LP 2.5, but due to its larger diameter, it 
requires surgical vascular access and hemostasis at the implantation site. The femoral or iliac 
artery is usually suitable for vascular access in human use. Due to smaller diameter and 
sharper curves of the vessels in the animals, vascular entry for the LP 5.0 was established 
through a vascular graft (GORE-TEX®Stretch Vascular Graft, W.L Gore & Associates, Inc., 
USA) sutured to the distal aorta with retroperitoneal access.  
4.10 Sampling techniques  
Labelled microspheres (Dye-Trak VII+®, Triton Technology, San Diego, CA) were injected 
into the left ventricle via a cardiac pigtail catheter with percutaneous technique. In the 
following two experiments, fluorescent beads were used (Dye-Trak F®, Triton Technology, 
San Diego, CA). Injections were made percutaneously into the left ventricle in paper 2 and 
directly into the left atrium in the surgical protocol. In all experiments, microspheres (15µ) 
dissolved in saline solution were injected. All reference blood samples were drawn from the 
right femoral artery starting immediately before the start of injections and lasting for 3 
minutes. Four different colors were used, in a randomized sequence. Tissue samples were 
collected from the right and left kidney cortex, the cerebral cortex, right ventricle and from 
the myocardium. The left ventricular samples were separated between regions and divided 
into subendocardial and subepicardial halves. Tissue- and reference blood samples were 
weighed. Next the tissue samples were dissolved in 1M KOH and thereafter the colored or 
fluorescent markers were separated from the microspheres using a solution of 2-Ethoxyethyl 
Acetate. Finally, tissue blood flow rates were calculated by spectrophotometry using 
matched glass cuvettes . In paper 1, readings were made using a color spectrophotometer 
(Hewlett Packard 8452A). In the two next experiments, readings were made using a fluoro 
spectrophotometer (Shimadzu RF-5301PC). 
Access for cerebral microdialysis and intracranial pressure (ICP) monitoring was established 
through a 0.5cm burr-hole 1cm lateral to the midline suture and 0.5 cm anterior to the 
coronal suture. The dura mater was incised with diathermy. The Codman MicroSensor ICP 
Transducer (Codman, Raynham, MA) was placed 2 cm into brain parenchyma and 
connected to a Codman ICP Express™ monitor (Codman). A microdialysis catheter with cut 
off 20 000 Dalton and membrane length 20 mm (CMA 70, Microdialysis AB, Solna, Sweden) 
was introduced 3 cm into cerebral parenchyma. The microdialysis catheter was perfused 
with CNS perfusion fluid (CMA Microdialysis AB, Solna, Sweden) at a rate of  0.3 µL/min, 
using a CMA 107 microdialysis pump (Microdialysis AB, Solna, Sweden). Microdialysis 
samples were collected in microvials (200µL, Microdialysis AB, Solna, Sweden ) that were 
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changed after 20 minutes and directly analyzed with respect to glucose, glycerol, lactate and 
pyruvate using photometric assay (CMA 600 Microdialysis Analyzer, Microdialysis AB, 
Solna , Sweden).  A total of 3 vials were analyzed in each experiment, one representing 
Baseline before VF, the next representing 0-20 minutes of VF and the final representing 20-40 
minutes of VF. 
Intravascular blood pressures were continuously monitored (HP, M108, Waltham, MA, US). 
Digital recordings and manual data logs were performed at the pre-specified time points. 
End-tidal CO2 was directly monitored from the ventilator (Cato M32000, Drägerwerk, 
Lübeck, Germany) and recordings were made at specified times. 
All blood samples were drawn from the intravascular sheaths. Samples were taken 
immediately before injection of microspheres. Full blood was samples were analyzed 
directly after sampling. Arterial and venous blood-gas analysis was performed on an 
automated blood gas/electrolyte analyzer (AVL Opti 3, Critical Care Analyzer, OPTI 
Medical  Systems inc. Roswell, GA, US). Full blood lactate samples were stored on ice and 
analyzed with amperiometric enzymoassay (ABL 800, Radiometer, Copenhaken, DK). 
Analysis was performed at the certified laboratory for clinical biochemistry, Haukeland 
University Hospital. 
5. Future perspectives 
5.1 Curremt PVAD status 
The use of a percutaneous assist device has been shown experimentally to be 
hemodynamically effective in persistent cardiac arrest. The available data suggest the device 
may be able to prevent cerebral ischemic injury for a prolonged period of ventricular 
fibrillation without simultaneous chest compressions and vasopressor. Furthermore, 
hemodynamic and clinical efficacy was found to be at least as good as optimal conventional 
therapy with open chest cardiac massage during cardiac arrest in a porcine model. 
Data from experimental cardiac arrest have demonstrated a promising area for potential 
clinical use of percutaneous left ventricular assist devices.  The efficacy of the Impella 2.5 
during experimental cardiac arrest indicate such a device can be useful as circulatory 
support for patients with cardiac arrest and extreme heart failure with severe organ hypo-
perfusion for a limited period of time. Adjunctive treatment to improve efficacy of such 
devices, particularly intervention to improve left ventricular filling, may be another focus of 
further research. The clinical role of percutaneous assist devices in cardiac collapse with 
absent or severely impaired spontaneous circulation yet remains to be established.  
5.2 Practical perspectives with the Impella LP 2.5 in acute hemodynamic collapse 
The LP 2.5 may offer rapid and uncomplicated hemodynamic support, can prevent cerebral 
ischemia and may achieve hemodynamics and outcomes comparable to optimal manual 
resuscitation during cardiac arrest. These findings indicate the device may find a role in the 
clinical treatment of cardiac arrest. During acute percutaneous intervention for coronary 
ischemia in patients with ischemic cardiac arrest, a percutaneous assist device may facilitate 
coronary revascularization and could improve outcomes in this setting by reducing the need 
for chest compressions, cardioversion and adrenaline. Further benefit may be achieved by 
reducing the left ventricular work-load after revascularization. 
Potentially, even less complicated deployment algorithms can be developed which may 
permit use of such devices in a broader clinical setting. Delivery can be performed via the 
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femoral, axillar, and the subclavian artery (116). Furthermore, trans-apical deployment of 
the device into the left ventricle through a chest wall puncture could be feasible with a 
device designed for antegrade delivery. Positioning can be confirmed with 
echocardiography, and with implantation-techniques independent of fluoroscopy, the 
device could potentially be useful also without available cardiac catheterization facilities.  
Accordingly, the clinical potential of the device might theoretically also include out-of 
hospital use. The future development of percutaneous assist device therapy in cardiac arrest 
may include percutaneously deployed right heart support systems and possibly the use of 
adjunctive medical or mechanical intervention for additional hemodynamic benefit. Clinical 
use for extended time periods during cardiac arrest can not be recommended from the 
current data. Fluid loading is potentially deleterious over time for patients with 
compromised left ventricular function due to acute myocardial infarction. As with 
conventional CPR, the use of LVAD support if spontaneous heart function can not be 
restored over a longer period of time, have ethical implications that need to be considered.  
6. Conclusions 
Limited clinical data have demonstrated hemodynamic efficacy and safety of the two 
PVADs in clinical use.  Experimental data with the Impella LP 2.5 have shown this PVAD 
device is able to sustain perfusion to the brain and myocardium during ischemic cardiac 
arrest in a porcine model. Fluid loading improved pump efficacy during cardiac arrest. 
Furthermore, cerebral microdialysis indicated that the percutaneous LVAD can prevent 
cerebral injury during prolonged cardiac arrest. The hemodynamic effects of the device and 
its effects on tissue perfusion and cerebral ischemia can be maintained for an extended 
period of VF and may be continuously assessed with end-tidal CO2 from the ventilator. 
The Impella LP 2.5 device maintained hemodynamics and tissue perfusion comparable to 
open chest cardiac compressions during 15 minutes of VF in a porcine model and obtained 
similar rates of return of spontaneous circulation after defibrillation compared with open 
chest cardiac massage. A larger surgically implanted assist device of similar design did not 
improve results in this experimental model. 
Percutaneous left ventricular assist devices may be able to fill a void in the acute treatment 
of patients with acute hemodynamic collapse. With relative ease of deployment, low risk of 
procedural complications and beneficial hemodynamic effects, such devices should have 
potential to improve outcomes in patients with refractory cardiogenic shock and persistent 
ventricular fibrillation. These patients constitute a significant population in contemporary 
clinical practice which still have a very high mortality with current treatment. PVAD 
support can offer myocardial pressure- and ischemia unloading as well as improvement of 
vital organ perfusion in critically ill patients without the potential hazards of vasopressors 
and mechanical compression devices. By reducing intra-cardiac pressures, myocardial 
oxygen consumption and by augmenting myocardial blood delivery, such devices may be 
able to increase the likelihood for successfully reversing a catastrophic state of refractory 
hemodynamic collapse as in persistent cardiac arrest and cardiogenic shock. Although 
limited clinical data are available this far. Experimental studies with the Impella LP 2.5 in 
ischemic ventricular fibrillation indicate a possible clinical potential. Further clinical studies 
should be warranted.  
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